Valbenazine Tosylate
Brand names: Ingrezza
At a glance
- Medicare prescriptions, 2024
- 192,441
- Medicare drug cost
- $1.45B
- Average cost per prescription
- $7,536
- Clinicians who prescribed it
- 8,287
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia. - chorea associated with Huntington’s disease.
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatric Nurse Practitioners 28.2%
- Psychiatry 26.1%
- Neurology 13.5%
- Nurse Practitioners 10.1%
- Internal Medicine 6.2%
- Family Medicine 5.8%
- Physician Assistants 5.3%
- Geriatric Medicine 1.3%
- Child & Adolescent Psychiatry 0.8%
- General Practice 0.6%
- Hospitalist 0.4%
- Cardiology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 197% from 2019 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Neurocrine Biosciences, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | purple capsule, 18 mm | VBZ 40 |
| 40 mg | white capsule, 22 mm | VBZ 40 |
| 60 mg | purple capsule, 18 mm | VBZ 60 |
| 60 mg | white capsule, 22 mm | VBZ 60 |
| 80 mg | purple capsule, 19 mm | VBZ 80 |
| 80 mg | white capsule, 22 mm | VBZ 80 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $17.3M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Neurocrine Biosciences, Inc. $17.3M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.